Cassava Sciences INC 8-K filings

Filana Therapeutics reported Q2 2026 financial results, showing reduced operating expenses and net loss, while continuing to address an FDA clinical hold on its TSC-related epilepsy therapy.

Filana Therapeutics, Inc. announced amendments to its 2018 Omnibus Incentive Plan, approved by stockholders at the 2026 Annual Meeting, increasing authorized shares and extending the plan's term.

Filana Therapeutics reported Q1 2026 financial results, highlighting a reduced net loss and cash burn, while advancing its simufilam program for TSC-related epilepsy.

Michael ODonnell will resign from the Filana Therapeutics Board of Directors at the company's 2026 annual meeting.

Filana Therapeutics reported a significant net loss increase in 2025, driven by a non-recurring gain in the prior year, while actively addressing an FDA clinical hold on its TSC-related epilepsy program.

Cassava Sciences announced the closure of the U.S. Department of Justice's inquiry into research misconduct allegations, ending all federal investigations.

Cassava Sciences, Inc. has reached a binding settlement agreement to resolve consolidated securities class action lawsuits for $31.25 million.

Cassava Sciences, Inc. announced the appointment of Dawn C. Bir to its Board's Compensation Committee, effective December 18, 2025, amending a previous 8-K filing.

Cassava Sciences' planned clinical trial for simufilam in TSC-related epilepsy is now on full clinical hold by the FDA, delaying its initiation.

Cassava Sciences' Board approved 2025 cash bonuses for its CEO and CFO, recognizing achievements in simufilam's TSC-related epilepsy exploration and team building.

Cassava Sciences, Inc. received notification from the FDA requiring additional information for its investigational new drug application for simufilam in tuberous sclerosis complex-related epilepsy.

Cassava Sciences reported a reduced net loss in Q3 2025, with $106.1 million cash, and is progressing simufilam for TSC-related epilepsy towards a H1 2026 clinical study.

A U.S. District Court dismissed with prejudice the criminal indictment against Dr. Hoau-Yan Wang, a former scientific collaborator of Cassava Sciences, Inc.

Cassava Sciences, Inc. has expanded its Board of Directors to eight members with the appointment of seasoned biopharmaceutical executive Dawn C. Bir.

Cassava Sciences, Inc. has furnished its September 2025 corporate presentation, making it available on its website.

Cassava Sciences reported a Q2 2025 net loss of $44.2 million, shifting its development focus to simufilam for TSC-related epilepsy with a clinical study planned for H1 2026, and recorded a $31.25 million litigation loss contingency.

Cassava Sciences announced positive preclinical results for simufilam in a mouse model of TSC-related epilepsy, showing attenuated seizure progression.

Cassava Sciences announced compelling preclinical data demonstrating simufilam's efficacy in reducing seizures in a mouse model of Tuberous Sclerosis Complex (TSC)-related epilepsy, supported by a favorable human safety profile from prior Phase 3 Alzheimer's studies, with plans to initiate human clinical trials in the first half of 2026.

Cassava Sciences, Inc. announced significant increases in cash and equity compensation for its non-employee directors, approved by stockholders at the 2025 Annual Meeting, alongside the election of directors and ratification of auditors, though a proposal to reduce board classification failed.

Cassava Sciences announces Q1 2025 financial results, highlights a new license agreement with Yale University, leadership appointments, and a strategic shift towards developing simufilam for TSC-related epilepsy.

Cassava Sciences announces the retirement of Chief Medical Officer James W. Kupiec, effective May 9, 2025, and the appointment of Jack Moore as Senior Vice President, Clinical Development, starting April 28, 2025.

Cassava Sciences discontinues its Alzheimer's disease program following disappointing Phase 3 trial results for simufilam.

Cassava Sciences amended its 2020 Cash Incentive Bonus Plan to comply with a court order, modifying bonus conditions related to market capitalization increases and FDA approval of simufilam.

Cassava Sciences reports its 2024 financial results, including a net loss of $24.3 million, and provides a business update, including the expected topline data release for the REFOCUS-ALZ study and a new license agreement for simufilam in TSC-related seizures.

Cassava Sciences secures an exclusive license from Yale University for intellectual property rights related to simufilam, a potential treatment for seizures associated with rare neurodevelopmental disorders like tuberous sclerosis complex (TSC).

Cassava Sciences is reducing its workforce by 33% and incurring $0.4 million in costs after a Phase 3 trial failed to meet its primary endpoints, while also providing a business update including cash position.

Cassava Sciences announced that its Phase 3 ReThink-ALZ study of simufilam for Alzheimer's disease did not meet its primary endpoints, leading to the discontinuation of two other related studies.

Cassava Sciences anticipates releasing top-line results from its 52-week Phase 3 RETHINK-ALZ trial of simufilam for Alzheimer's disease by the end of 2024, with $149 million in cash reserves to support operations into 2026.

Cassava Sciences has completed its ReTHINK Phase 3 clinical trial, settled with the SEC for $40 million, and is preparing to release top-line results by the end of the year.

Cassava Sciences has disclosed the finalized compensation terms for its new CEO, Richard Barry, including a base salary, bonus potential, and stock options.